Abstract Type 1 diabetes (T1D) results from complex interactions between genetic and environmental factors. The nonobese diabetic (NOD) mouse develops spontaneous T1D and has been used extensively to study the genetic control of this disease. T1D is suppressed in NOD mice congenic for the C57BL/10 (B10)-derived Idd9 resistance region on chromosome 4. Previous studies conducted by other investigators have identified four subregions (Idd9.1, Idd9.2, Idd9.3, and Idd9.4) where B10-derived genes suppress T1D development in NOD mice. We independently generated and characterized six congenic strains containing B10-derived intervals that partially overlap with the Idd9.1 and Idd9.4 regions. T1D incidence studies have revealed a new B10-derived resistance region proximal to Idd9.1. Our results also indicated that a B10-derived gene(s) within the Idd9.4 region suppressed the diabetogenic activity of CD4 T cells and promoted CD103 expression on regulatory T cells indicative of an activated phenotype. In addition, we suggest the presence of a B10-derived susceptibility gene(s) in the Idd9.1/Idd9.4 region. These results provide additional information to improve our understanding of the complex genetic control by the Idd9 region.
Type 1 diabetes (T1D) in both human and nonobese diabetic (NOD) mice is a polygenic autoimmune disease caused by T cell-mediated destruction of pancreatic β-cells (Driver et al. 2011; Todd 2010) . Excess inflammation generated by innate immunity participates in the initiation of autoimmune diabetes in the NOD mouse model as well as in humans (Chen et al. 2014; Diana et al. 2013; Ferreira et al. 2014; Kallionpaa et al. 2014 ). This in turn leads to activation and accumulation of autoreactive T cells that contribute to subsequent stages of the disease. Both CD4 and CD8 T cells participate in the development of T1D (Christianson et al. 1993; DiLorenzo et al. 1998) . Pathogenic CD4 T cells promote T1D development by secreting inflammatory cytokines, enhancing the immunogenic functions of antigen-presenting cells, and providing help to cytotoxic CD8 T cells. Pathogenic CD8 T cells directly kill pancreatic β-cells through the recognition of peptides presented by major histocompatibility complex (MHC) class I molecules. Autoreactive T cells can be controlled by FOXP3+ regulatory CD4 T cells (Tregs) (Bettini and Vignali 2009; Jeker et al. 2012) . Cellular and genetic defects associated with Tregs have been reported in both NOD mice and T1D patients (Garg et al. 2012; Gregg et al. 2004; Lindley et al. 2005; Long et al. 2010; McClymont et al. 2011; Pop et al. 2005; Tritt et al. 2008; Yamanouchi et al. 2007 ). NOD mice have been used extensively to study the genetic factors contributing to T1D development (Driver et al. 2011; Wicker et al. 2005) . While the H2 g7 haplotype provides the primary component of T1D susceptibility in NOD mice, it alone is not sufficient for disease development (Driver et al. 2011) . In conjunction with the H2 g7 MHC, other insulin-dependent diabetes susceptibility (Idd) genes are also required to interactively contribute to the Bixuan Lin and Ashley E. Ciecko contributed equally to this work.
development of diabetogenic T cell responses in NOD mice (Driver et al. 2011) . Similarly, human genome-wide association studies have also revealed more than 40 non-MHC genetic loci associated with T1D risk (Barrett et al. 2009; OnengutGumuscu et al. 2015) .
The Idd9/Idd11 genetic loci located on mouse chromosome 4 are particularly complex regions contributing to T1D susceptibility or resistance and have been the interest of many studies (Brodnicki et al. 2005; Cannons et al. 2005; HamiltonWilliams et al. 2010 HamiltonWilliams et al. , 2013 Kachapati et al. 2012; Lyons et al. 2000; Tan et al. 2010; Yamanouchi et al. 2010) . NOD mice congenic for the C57BL/10 (B10)-derived Idd9 region are highly resistant to T1D development when compared to NOD mice (Lyons et al. 2000) . Subsequent analyses revealed that B10 Idd9-mediated diabetes resistance is caused by the cumulative protective effect of at least four subregions named Idd9.1, Idd9.2, Idd9.3, and Idd9.4 (Hamilton-Williams et al. 2013 ). Parallel to these Idd9 mapping studies conducted by other laboratories, we independently backcrossed the previously reported line 905 (Hamilton-Williams et al. 2013) to NOD/LtDvs (NOD hereafter) mice, genotyped microsatellite and single nucleotide polymorphism (SNP) markers to screen for recombination, and generated three distinct subcongenic strains (lines 1 to 3 in Fig. 1 ). The B10-derived regions in lines 1 to 3 overlap to various extents with the recently redefined Idd9.1 and Idd9.4 loci ( Fig. 1 and ( Hamilton-Williams et al. 2013) ). We redefined the proximal boundary of line 905 and confirmed it to be the same in lines 1-3 (between rs27499480 and rs27516145, NOD and B10 are identical by descent in this region, Fig. 1 ). Diabetes incidence was followed in female mice by weekly testing urine glucose using Diastix (Bayer). Mice were considered diabetic after two consecutive readings of ≥250 mg/dL. Diabetes incidence was plotted by KaplanMeier curves and compared by the log-rank test using the Prism software (Graphpad). T1D development in lines 1-3 was significantly suppressed when compared to that in NOD mice (p < 0.0001, Fig. 2a) .
To further refine the diabetes resistance region(s) present in lines 1 and 2, we backcrossed these stocks to NOD mice respectively to create line 6 as well as lines 4 and 5 (Fig. 1) . Diabetes incidence studies did not reveal any difference between lines 4 to 6 and standard NOD mice (Fig. 2b, c) . Since T1D was suppressed in line 2 but not in lines 4 and 5, the results suggest a novel B10-derived region (between rs13477946 and D4Mit11) conferring diabetes resistance in NOD mice. However, we cannot completely rule out the possibility that the congenic region in line 4 contains a resistance gene that is not sufficient to confer diabetes suppression on its own or its T1D-protective effect is masked by another B10-derived susceptibility gene, similar to the case of line 5 discussed below. Therefore, we define the newly identified B10 resistance region (tentatively named Idd9.5) as the segment between rs27516145 and D4Mit11 (Fig. 1) . We searched Mouse Genome Informatics (www.informatics. jax.org) for genes mapped to the Idd9.5 region. The 3.47-Mb Idd9.5 region contains 65 genes of which Zfp69 has been shown to be differentially expressed between NOD and B10 alleles (Berry et al. 2015) . Zfp69 represents a potential candidate gene as it has been linked to obesity-associated diabetes and modulation of hepatic insulin sensitivity in mice (Chung et al. 2015; Scherneck et al. 2009 ). Although a role of Zfp69 in the immune system has not been reported, its function in regulating insulin sensitivity may indirectly contribute to T1D.
The lack of T1D protection in line 5 was unexpected since it harbors the entire Idd9.1 region defined by Hamilton-Williams et al. 2013 and Idd11 mapped in Tan et al. 2010 (Fig. 1) , and B10 and B6 alleles of the Idd11 candidate gene AK005651 (also known as 1700003M07Rik) are identical. This observation suggested the presence of a B10 diabetes susceptibility region in line 5 that masked the T1D-protective effect of B10 Idd9.1. This possibility is also supported by the comparison between lines 1 and 3, and between lines 2 and 3. Although lines 1 and 3 did not differ from each other, Line 2 was significantly less protected than line 3 (p = 0.0305, Fig. 2a) , suggesting a B10 susceptibility region between rs27516779 and D4Mit71 that partially overlap with Idd9.1 and Idd9.4 (Fig. 1) . Analyses of ) from NOD or lines 1-3 were followed for diabetes incidence. Statistical analysis was performed using the log-rank test additional congenic strains are required to confirm and further define this B10 susceptibility locus. Direct comparison between lines 2 and 3 also indicates the B10 resistance interval between rs13459077 and rs3718220 ( Fig. 1) , likely representing the previously reported Idd9.4 region (Hamilton-Williams et al. 2013) .
We have previously observed that genes within the NORderived Idd9/Idd11 resistance region regulates the diabetogenic activity of CD4 T cells (Chen et al. 2008; Stolp et al. 2012) . Other studies have also demonstrated that the B10 Idd9-protective effect is in part mediated by CD4 T cells (Hamilton-Williams et al. 2010; Waldner et al. 2006; Yamanouchi et al. 2010) . Therefore, we asked if the diabetogenic activity of CD4 T cells isolated from lines 1-3 was suppressed compared to that of the NOD counterparts. β-cell-autoreactive CD8 T cells of the NY8.3 clonotype require CD4 T cell help to fully exert their diabetogenic function (Serra et al. 2003; Verdaguer et al. 1997) . We obtained NOD.NY8.3 (stock# 005868) and NOD. Rag1 −/− (stock# 003729) mice from the Jackson Laboratory to subsequently generate through interbreeding the NOD.Rag1
.NY8.3 strain. We then purified splenic CD4 T cells from 7-to 8-week-old NOD as well as lines 1-3 mice by the previously described magnetic bead system (Chen et al. 2008 ) and intravenously transferred them (5 × 10 6 cells) into 7-to 8-week-old NOD.Rag1
.NY8.3 recipients to test their diabetogenic activity. Purity of the isolated CD4 T cells was routinely verified by flow cytometry to be higher than 92%. Female mice were used for both donors and recipients. T1D development in the CD4 T cell recipients was monitored as described above. CD4 T cells isolated from line 3 was found to be significantly less diabetogenic than those from standard NOD mice (Fig. 3) . On the other hand, B10-derived congenic regions in lines 1 and 2 did not suppress the diabetogenic activity of the CD4 T cells (Fig. 3) . Further supporting the presence of a B10-derived disease susceptibility gene(s) in the line 2 congenic region was the finding that adoptively transferred CD4 T cells from this stock were more diabetogenic than those from standard NOD mice but not the counterparts from line 1 (Fig. 3) . Together, these results indicate that B10-derived Idd9.4 genes mediate T1D protection at the level of CD4 T cells.
The Idd9.1 interval described earlier by Yamanouchi et al. 2010 is within line 3 (Fig. 1) . This region was shown to regulate the development and function of CD4+ FOXP3+ regulatory T cells (Tregs). Thus, we compared the expression of a panel of markers (CD25, CTLA4, CD73, GITR, OX40, LAG-3, GARP, ICOS, CD137, and CD103) on splenic Tregs (identified as CD4+ FOXP3+) in 8-to 10-week-old standard NOD and line 3 congenic females by flow cytometry. We consistently observed a higher expression level of CD103, but not other markers, on Tregs in line 3 than in NOD mice (data not shown). We further compared the frequencies of CD103 + Tregs in the spleens and pancreatic lymph nodes (PLNs) of lines 1-3 to map the genetic region that controls the accumulation of this regulatory subset. Compared to standard NOD mice, we did not observe any difference in the frequency of total Tregs in lines 1-3 (Fig. 4a, c) . Consistent with our earlier studies, the percentages of CD103+ Tregs were higher in both the spleens and PLNs of line 3 than those in NOD mice (Fig. 4b, d ). On the other hand, the levels of CD103+ Tregs were comparable in spleens and PLNs between NOD mice and line 1 (Fig. 4b, d Statistical analysis is performed using the Mann-Whitney test NOD mice, the frequencies of CD103+ Tregs were found to be similar in the spleens but slightly lower in the PLNs of line 2 (Fig. 4b, d ). CD103 has been shown as a marker of activated Tregs (Huehn et al. 2004; Zhao et al. 2008) . Therefore, our results suggest that the Idd9.4 region genes control Treg activation and this phenotype likely contributed to the reduced diabetogenic activity of line 3 CD4 T cells in the adoptive transfer studies shown in Fig. 3 . In summary, we identified a novel Idd9 subregion (Idd9.5) that regulates T1D development in the NOD mouse model. Our studies also indicate that an Idd9.4 gene(s) controls the diabetogenic activity of CD4 T cells, possibly through enhancing Treg activation. Lastly, we suggest the presence of a B10 susceptibility gene(s) in the Idd9.1/Idd9.4 region. Our studies provide additional insight into the complexity of the Idd9-mediated T1D genetic control.
